Request Your Free Digital Poster (PDF)
This poster presents the typical workflow for Bio-Rad's anti-idiotypic antibody projects using generation and characterization of antibodies against the checkpoint inhibitor drug ipilimumab (YERVOY) as an example.
Antibodies in monovalent Fab format were characterized for specificity, affinity, and inhibitory potential, and were screened for their ability to work in a pharmacokinetic bridging ELISA for drug quantification. Selected Fab antibodies were converted into full length, fully human IgG1 format and evaluated in an anti-drug-antibody bridging ELISA.
Inhibitory antibodies that recognize the free drug, and antibodies that recognize the drug-target complex were developed and are available in our catalog.
Need anti-idiotypic antibodies to your original biologic?
Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. HuCAL and HuCAL PLATINUM are trademarks of MorphoSys AG. All trademarks used herein are the property of their respective owner.